CVS Health (CVS) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
CVS Health Corporation (CVS) insider buying and selling: 4 purchases, 5 sales
54 Form 4 Table I transactions filed with the SEC by CVS Health Corporation insiders between 2025-08-29 and 2026-06-29 (15-month history): 4 open-market purchases and 5 sales, plus 45 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a sale of $187.3M by Robbins Larry on 2026-05-19.
CVS Health insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, CVS Health insiders filed 4 sales worth $323.7M on the open market, and no purchases.
The biggest seller was Robbins Larry (Director): $317.5M in 3 sales, out of 2 different sellers.
The largest trade of the period was a sale of $187.3M on May 19, 2026, by Robbins Larry (Director). Form 4 on sec.gov (0000905148-26-002617).
None of the 4 sales carries the 10b5-1 plan flag on the Form 4 (sales scheduled months ahead).
The last three months show 0 sales, against 4 in the three before. The latest sale from May 21, 2026.
Against its sector (Healthcare, 59 companies with an insider page on this site), over the same dates the median is 9 sales and 0 purchases on the open market. CVS Health has more sales than 14 of the other 58, ranks 4 of 59 by net dollars sold, and 19 of the 59 have at least one purchase.
The 20 most important trades
The 4 open-market purchases first, then the rest, each type from largest to smallest. The full history is in the tool above, already searched.
See all 54 CVS trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2024-10-23 | 2025-10-14 | Capozzi Heidi B | EVP and Chief People Officer | $2k | P — Open-market purchase Indirect holding, through: By Trust Form 4 footnoteF1 Shares purchased by a broker exercising discretion for a managed account in the name of a trust for the benefit of the Reporting Person's spouse that were not previously reported due to an error on the part of the broker. | SEC |
| 2024-09-09 | 2025-10-14 | Capozzi Heidi B | EVP and Chief People Officer | $2k | P — Open-market purchase Indirect holding, through: By Trust Form 4 footnoteF1 Shares purchased by a broker exercising discretion for a managed account in the name of a trust for the benefit of the Reporting Person's spouse that were not previously reported due to an error on the part of the broker. | SEC |
| 2025-01-23 | 2026-01-27 | Nelson Steven H | EVP and President, Aetna | $1k | P — Open-market purchase Indirect holding, through: By Trust Form 4 footnoteF1 Shares purchased by a broker exercising discretion for a separately managed account in the name of a trust for the benefit of the Reporting Person that were not previously reported due to an error on the part of the broker. The shares were subsequently transferred to a trust for the benefit of the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership of these shares. | SEC |
| 2024-10-02 | 2025-10-14 | Capozzi Heidi B | EVP and Chief People Officer | $622 | P — Open-market purchase Indirect holding, through: By Trust Form 4 footnoteF1 Shares purchased by a broker exercising discretion for a managed account in the name of a trust for the benefit of the Reporting Person's spouse that were not previously reported due to an error on the part of the broker. | SEC |
| 2026-05-19 | 2026-05-21 | Robbins Larry | Director | $187.3M | S — Open-market sale Indirect holding, through: Held by Glenview Investment Funds 4 Form 4 footnotesF1 These shares of the Issuer's common stock (the "Shares") are held for the accounts of Glenview Capital Master Fund, Ltd., Glenview Offshore Opportunity Master Fund, Ltd. (the "GO Fund"), Glenview Healthcare Master Fund, L.P., and GCM Suggestivist I Master Fund, L.P. (collectively, the "Glenview Investment Funds"). F2 This price reflects the weighted average price for open-market sales of Shares on May 19, 2026 within a $1.00 range. The actual prices for these transactions range from $94.18 to $95.175, inclusive. The Reporting Person further undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares sold at each separate price. F3 The Reporting Person disclaims beneficial ownership over any securities owned by the Glenview Investment Funds other than to the extent of any pecuniary interest he may have therein. F4 The Glenview Investment Funds are the record holders of the Shares. The Reporting Person is the Founder, Portfolio Manager and CIO of Glenview Capital Management, LLC, which serves as investment manager to each of the Glenview Investment Funds. The Reporting Person shares voting and dispositive power over the Shares held by the Glenview Investment Funds and may be deemed to beneficially own such Shares. | SEC |
| 2026-05-20 | 2026-05-21 | Robbins Larry | Director | $95.5M | S — Open-market sale Indirect holding, through: Held by Glenview Investment Funds 7 Form 4 footnotesF1 These shares of the Issuer's common stock (the "Shares") are held for the accounts of Glenview Capital Master Fund, Ltd., Glenview Offshore Opportunity Master Fund, Ltd. (the "GO Fund"), Glenview Healthcare Master Fund, L.P., and GCM Suggestivist I Master Fund, L.P. (collectively, the "Glenview Investment Funds"). F5 This price reflects the weighted average price for open-market sales of Shares on May 20, 2026 within a $1.00 range. The actual prices for these transactions range from $93.25 to $94.19, inclusive. The Reporting Person further undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares sold at each separate price. F3 The Reporting Person disclaims beneficial ownership over any securities owned by the Glenview Investment Funds other than to the extent of any pecuniary interest he may have therein. F4 The Glenview Investment Funds are the record holders of the Shares. The Reporting Person is the Founder, Portfolio Manager and CIO of Glenview Capital Management, LLC, which serves as investment manager to each of the Glenview Investment Funds. The Reporting Person shares voting and dispositive power over the Shares held by the Glenview Investment Funds and may be deemed to beneficially own such Shares. F6 This price reflects the weighted average price for open-market sales of Shares on May 20, 2026 within a $1.00 range. The actual prices for these transactions range from $94.25 to $95.245, inclusive. The Reporting Person further undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares sold at each separate price. F7 This price reflects the weighted average price for open-market sales of Shares on May 20, 2026 within a $1.00 range. The actual prices for these transactions range from $95.25 to $96.21, inclusive. The Reporting Person further undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares sold at each separate price. F8 This price reflects the weighted average price for open-market sales of Shares on May 20, 2026 within a $1.00 range. The actual prices for these transactions range from $96.25 to $96.34, inclusive. The Reporting Person further undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares sold at each separate price. | SEC |
| 2026-05-21 | 2026-05-21 | Robbins Larry | Director | $34.6M | S — Open-market sale Indirect holding, through: Held by Glenview Investment Funds 4 Form 4 footnotesF1 These shares of the Issuer's common stock (the "Shares") are held for the accounts of Glenview Capital Master Fund, Ltd., Glenview Offshore Opportunity Master Fund, Ltd. (the "GO Fund"), Glenview Healthcare Master Fund, L.P., and GCM Suggestivist I Master Fund, L.P. (collectively, the "Glenview Investment Funds"). F9 This price reflects the weighted average price for open-market sales of Shares on May 21, 2026 within a $1.00 range. The actual prices for these transactions range from $93.125 to $93.83, inclusive. The Reporting Person further undertakes to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of Shares sold at each separate price. F3 The Reporting Person disclaims beneficial ownership over any securities owned by the Glenview Investment Funds other than to the extent of any pecuniary interest he may have therein. F4 The Glenview Investment Funds are the record holders of the Shares. The Reporting Person is the Founder, Portfolio Manager and CIO of Glenview Capital Management, LLC, which serves as investment manager to each of the Glenview Investment Funds. The Reporting Person shares voting and dispositive power over the Shares held by the Glenview Investment Funds and may be deemed to beneficially own such Shares. | SEC |
| 2026-05-08 | 2026-05-11 | Mandadi Tilak | EVP, Chief Exp & Tech Officer | $6.2M | S — Open-market saleForm 4 footnoteF1 All shares sold at an Average price between $89.30 and $89.81. | SEC |
| 2025-08-20 | 2025-08-29 | Finucane Anne A. | Director | $533k | S — Open-market sale Indirect holding, through: By Trust Form 4 footnoteF1 Sale of shares by the reporting person not timely reported due to an administrative error. | SEC |
| 2026-03-31 | 2026-04-02 | Joyner J. David | President, CEO and Chair | $6.2M | A — Grant or awardForm 4 footnoteF1 Consists of restricted stock units awarded pursuant to Issuer's 2017 Incentive Compensation Plan. Restrictions lapse in three equal installments, commencing 3/31/2027. | SEC |
| 2026-05-20 | 2026-05-22 | Aguirre Fernando | Director | $2.9M | D — Sale back to the issuerForm 4 footnoteF1 Represents weighted average purchase price for this group of purchases, which occurred on the same day. Multiple purchases were conducted, with prices ranging between $93.50 and $94.01 per share. | SEC |
| 2026-03-31 | 2026-04-02 | Shah Prem S | EVP and Group President | $1.8M | A — Grant or awardForm 4 footnoteF1 Consists of restricted stock units awarded pursuant to Issuer's 2017 Incentive Compensation Plan. Restrictions lapse in three equal installments, commencing 3/31/2027. | SEC |
| 2026-03-31 | 2026-04-02 | Mandadi Tilak | EVP, Chief Exp & Tech Officer | $1.6M | A — Grant or awardForm 4 footnoteF1 Consists of restricted stock units awarded pursuant to Issuer's 2017 Incentive Compensation Plan. Restrictions lapse in three equal installments, commencing 3/31/2027. | SEC |
| 2026-03-31 | 2026-04-02 | Nelson Steven H | EVP and President, Aetna | $1.6M | A — Grant or awardForm 4 footnoteF1 Consists of restricted stock units awarded pursuant to Issuer's 2017 Incentive Compensation Plan. Restrictions lapse in three equal installments, commencing 3/31/2027. | SEC |
| 2026-03-31 | 2026-04-02 | Newman Brian | EVP, Chief Financial Officer | $1.4M | A — Grant or awardForm 4 footnoteF1 Consists of restricted stock units awarded pursuant to Issuer's 2017 Incentive Compensation Plan. Restrictions lapse in three equal installments, commencing 3/31/2027. | SEC |
| 2025-08-31 | 2025-09-02 | Mandadi Tilak | EVP, Chief Exp & Tech Officer | $939k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF1 Surrender of shares in payment of withholding taxes due upon the vesting and settlement of restricted stock units. | SEC |
| 2026-03-31 | 2026-04-02 | Khichi Samrat S. | EVP, CPO and General Counsel | $900k | A — Grant or awardForm 4 footnoteF1 Consists of restricted stock units awarded pursuant to Issuer's 2017 Incentive Compensation Plan. Restrictions lapse in three equal installments, commencing 3/31/2027. | SEC |
| 2026-03-31 | 2026-04-02 | Clark James David | SVP, Cont & Chief Acct Officer | $800k | A — Grant or awardForm 4 footnoteF1 Consists of restricted stock units awarded pursuant to Issuer's 2017 Incentive Compensation Plan. Restrictions lapse in three equal installments, commencing 3/31/2027. | SEC |
| 2025-11-30 | 2025-12-02 | Farah Roger N | Director | $783k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF1 Surrender of shares in payment of withholding taxes due upon the vesting and settlement of a restricted stock unit award. | SEC |
| 2025-11-30 | 2025-12-02 | Capozzi Heidi B | EVP and Chief People Officer | $761k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF1 Surrender of shares in payment of withholding taxes due upon the vesting and settlement of a restricted stock unit award. | SEC |
The period balance: money in, money out
Across the Form 4 filings submitted between Aug 29, 2025 and Jun 29, 2026, CVS Health Corporation open-market activity adds up to 4 purchases worth $6k and 5 sales worth $324.2M. The net balance is $324.2M on the sell side.
Only codes P and S count, where an insider puts in or takes out their own money. A selling balance like CVS Health Corporation's is the norm in the S&P 500, where much of the pay comes as stock. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| A | Grant or award | 24 | $17.3M |
| F | Tax withholding (shares surrendered for taxes) | 19 | $7.0M |
| S | Open-market sale | 5 | $324.2M |
| P | Open-market purchase | 4 | $6k |
| D | Sale back to the issuer | 2 | $3.0M |
| Total | Everything filed in the period | 54 | $351.6M |
All 54 rows carry an amount: the column adds up what was filed, no estimates. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 20 distinct people or entities have filed CVS Health Corporation transactions: 2 bought on the open market and 3 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Robbins Larry | Director | 3 | — | $317.5M (3) | 2026-05-21 |
| Mandadi Tilak | EVP, Chief Exp & Tech Officer | 5 | — | $6.2M (1) | 2026-05-11 |
| Finucane Anne A. | Director | 2 | — | $533k (1) | 2025-11-21 |
| Capozzi Heidi B | EVP and Chief People Officer | 6 | $5k (3) | — | 2026-04-02 |
| Nelson Steven H | EVP and President, Aetna | 3 | $1k (1) | — | 2026-04-02 |
| Aguirre Fernando | Director | 4 | — | — | 2026-05-22 |
| Clark James David | SVP, Cont & Chief Acct Officer | 4 | — | — | 2026-06-29 |
| Shah Prem S | EVP and Group President | 4 | — | — | 2026-04-02 |
Shown here are the 8 who moved the most money, out of 20. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was May 2026: 0 purchases and 4 sales, worth $323.7M. 13 of the 15 months have none. 4 trades were executed before the window opens and filed late: they are in the history and in the tables above, but fall outside this calendar.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 0 | $0 | 1 | $533k |
| Sep 2025 | 0 | $0 | 0 | $0 |
| Oct 2025 | 0 | $0 | 0 | $0 |
| Nov 2025 | 0 | $0 | 0 | $0 |
| Dec 2025 | 0 | $0 | 0 | $0 |
| Jan 2026 | 0 | $0 | 0 | $0 |
| Feb 2026 | 0 | $0 | 0 | $0 |
| Mar 2026 | 0 | $0 | 0 | $0 |
| Apr 2026 | 0 | $0 | 0 | $0 |
| May 2026 | 0 | $0 | 4 | $323.7M |
| Jun 2026 | 0 | $0 | 0 | $0 |
| Jul 2026 | 0 | $0 | 0 | $0 |
| Aug 2026 | 0 | $0 | 0 | $0 |
| Sep 2026 | 0 | $0 | 0 | $0 |
| Oct 2026 | 0 | $0 | 0 | $0 |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
CVS Health Corporation (CVS) analysis page →
Other Healthcare companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
None of the 5 sales in the table is flagged as scheduled (10b5-1 plan), the kind signed months ahead and executed automatically. CVS Health's 4 open-market purchases (code P) are the rare signal: insiders are already paid in stock, so buying more means putting in their own money. The latest filing is from Jun 29, 2026, and a Form 4 arrives up to two business days after the trade.
20 of the 20 rows in the table carry footnotes from the Form 4 itself, folded into the code column and copied verbatim; a row with no footnote means the filing has none.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.